Latest News and Press Releases

– Preclinical data demonstrate pharmacodynamic activity of KRIYA-586, an investigational gene therapy which encodes for an anti-IGF1R antibody – – Kriya anticipates advancing KRIYA-586 into the...

– Dr. Wright has three decades of experience in the research and development of viral vectors and has been involved in the development of multiple approved gene therapies globally – PALO ALTO, Calif....

PALO ALTO, Calif., and RESEARCH TRIANGLE PARK, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common...

– Kriya is developing KRIYA-825 as a potential one-time gene therapy expressing a fusion protein inhibiting the activity of complement C3 and C5 for the treatment of Geographic Atrophy – PALO...

– Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic disease and neurology – – Company to host symposium on “Advancing Gene...

– KRIYA-586 is designed to be a one-time treatment delivered by focal peribulbar injection, that encodes an antibody blocking the Insulin-Like Growth Factor 1 Receptor (IGF-1R), a clinically validated...

PALO ALTO, Calif., and RESEARCH TRIANGLE PARK, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common...

– Everads' next generation suprachoroidal delivery technology enables targeted drug delivery to the retina, which Kriya intends to use for multiple ophthalmology gene therapy product candidates – ...